Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study

Emerging experience with meningococcal serogroup B protein vaccines

(2017) Daniela Toneatto et al.   Expert Review of Vaccines

Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial

(2017) Mildred A. Iro et al.   VACCINE

Immunogenicity and safety of concomitant administration of meningococcal serogroup B (4CMenB) and serogroup C (MenC-CRM) vaccines in infants: A phase 3b, randomized controlled trial

(2017) Marco Aurelio P. Safadi et al.   VACCINE

The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004–2014

(2017) Robert Whittaker et al.   VACCINE

Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements

(2016) Federico Martinón-Torres   JOURNAL OF ADOLESCENT HEALTH

The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines

(2016) Stephen I. Pelton   JOURNAL OF ADOLESCENT HEALTH

Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study

(2016) Sydel R Parikh et al.   LANCET

Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age

(2016) Matthew D. Snape et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine in healthy adolescents in Korea—A randomised trial

(2016) Hoan Jong Lee et al.   VACCINE

Meningococcal disease in the Asia-Pacific region: Findings and recommendations from the Global Meningococcal Initiative

(2016) Ray Borrow et al.   VACCINE

Global incidence of serogroup B invasive meningococcal disease: a systematic review

(2015) Shruti Sridhar et al.   LANCET INFECTIOUS DISEASES

The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations

(2015) Marco Aurélio P. Sáfadi et al.   VACCINE

A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I)

(2014) Roman Prymula et al.   Human Vaccines & Immunotherapeutics

A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program

(2013) Miguel O’Ryan et al.   DRUGS

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials

(2013) Timo Vesikari et al.   LANCET

Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules

(2012) Nicoletta Gossger et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION